Aclaris Therapeutics vs Evommune
ACRS and EVMN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACRS and EVMN compare
Aclaris Therapeutics is the larger company, worth 2.1 times as much as Evommune ($577M against $277M).
Aclaris Therapeutics grew revenue faster over the last twelve months (−59.3% versus −100% for Evommune).
Evommune scores higher on the StockData Score (7 against 6 for Aclaris Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACRS | EVMN |
|---|---|---|
| Size and price | ||
| Market cap | $577M | $277M |
| Share price | $3.92 | $7.63 |
| Change, 1 year | 62.7% | −60.9% |
| Change, 5 years | −71.6% | – |
| Beta (5Y) | 1.13 | 0.79 |
| Employees | 73 | 48 |
| StockData Score | ||
| Total score | 6 | 7 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 90.1× | – |
| P/B | 3.5× | 1.1× (better) |
| FCF yield | −13.1% (better) | −32.9% |
| Growth | ||
| Revenue growth (TTM) | −59.3% (better) | −100% |
| Revenue growth, 5Y average | 3.8% | – |
| Profitability | ||
| Gross margin | 79.2% | – |
| Operating margin | −1414% | – |
| Net margin | −1244% | – |
| FCF margin | −1177% | – |
| Return on equity | −55.5% (better) | −331% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 5.09 | 8.52 (better) |
| Altman Z-score | −0.44 | 3.85 (better) |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 82.3% | 95.4% |
| Held by insiders | 13.3% | 51.6% |
| Insider net buying, 12 months | −$1.4M (better) | −$2.1M |
| Short interest, % of float | 9.1% | 19.3% |
Go deeper
- ACRS stock overview
- ACRS income statement
- ACRS valuation and score
- EVMN stock overview
- EVMN income statement
- EVMN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.